IL-17A gene polymorphism rs2275913 is associated with the development of asthma after bronchiolitis in infancy

Abstract

The IL-17A rs2275913 (-197G>A) polymorphism decreased the risk of post-bronchiolitis asthma at 11-13 years of age, but not earlier in life, in the present prospective, long-term follow-up study.

IL17A gene polymorphisms rs4711998 and rs8193036 are not associated with postbronchiolitis asthma in Finnish children

“…This study followed up a cohort of 187 previously healthy, full‐term infants who were hospitalised for bronchiolitis at less than six months of age in 2001–2004 at Tampere University Hospital, Finland. We evaluated the associations of IL17A rs4711998 and rs8193036 polymorphisms with asthma, asthma medication and allergic rhinitis when they were 5–7 (n = 139) and 11–13 (n = 124) years of age .…”

“…At the control visits, current asthma was defined as continuous or intermittent ICS use for asthma during the preceding 12 months or as the presence of repeated doctor‐diagnosed wheezing episodes, prolonged cough during the preceding 12 months and diagnostic findings in the exercise challenge or bronchodilation tests . Persistent asthma was defined as the presence of asthma at both of the five to seven and 11–13 years control visits.…”

“…The IL-17 family members are pro-inflammatory cytokines predominantly secreted by T helper 17 (Th17) cells, and the IL-17A cytokine plays a role in asthma pathogenesis (1). Our prospective postbronchiolitis follow-up study revealed that IL17A rs2275913 single nucleotide polymorphism (SNP) was associated with postbronchiolitis asthma at 11-13 years of age, when the variant genotype and the minor allele were protective from asthma, but not at five to seven years of age or earlier (2).…”

“…Current asthma (N = 15) 8 (17.8%) p = 0.16 ‡ 5 (8.5%) 2 (10.5%) p = 0.81 § Persistent asthma (N = 9) 5 (11.1%) p = 0.23 ‡ 2 (3.4%) 2 (11.1%) p = 0.40 § Use of inhaled corticosteroids and bronchodilators in last 12 months (N = 11) 6 (13.3%) p = 0.20 ‡ 3 (5.1%) 2 (11.1%) p = 0.51 § Use of bronchodilators in last 12 months (N = 28) 13 (28.9%) p = 0.23 ‡ 12 (20.3%) 3 (16.7%) p = 0.40 § Allergic rhinitis symptoms in last 12 months (N = 19) 7 (15.6%) p = 1.00 ‡ hospitalised for bronchiolitis at less than six months of age in 2001-2004 at Tampere University Hospital, Finland. We evaluated the associations of IL17A rs4711998 and rs8193036 polymorphisms with asthma, asthma medication and allergic rhinitis when they were 5-7 (n = 139) and 11-13 (n = 124) years of age (2). The respiratory syncytial virus (RSV) was studied with antigen detection and polymerase chain reaction in nasopharyngeal aspirates obtained during hospitalisation in infancy.…”

Association between rs2275913 single‐nucleotide polymorphism of the interleukin‐17A gene and perioperative analgesic use in cosmetic orthognathic surgery

“…The AA genotype of the rs2275913 SNP of the IL‐17A gene is reportedly associated with a higher risk of asthma, bronchiolitis, ulcerative colitis, digestive cancer, gastric cancer, and cervical cancer . Other studies reported that the rs2275913 SNP had no association with pediatric systemic lupus erythematosus disease activity or cervical cancer and had opposite effects on rheumatoid arthritis, post‐bronchiolitis asthma at 11‐13 years of age and colorectal cancer . Overall, the AA genotype of the rs2275913 SNP appears to contribute to greater inflammation, leading to autoimmune‐related inflammatory diseases, including cancer.…”